E. Ohman J or Asset Management AB Buys Shares of 4,000 Revolution Medicines, Inc. $RVMD

E. Ohman J or Asset Management AB purchased a new stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) during the first quarter, HoldingsChannel.com reports. The fund purchased 4,000 shares of the company’s stock, valued at approximately $389,000.

A number of other large investors have also recently made changes to their positions in RVMD. Indiana Trust & Investment Management Co purchased a new stake in Revolution Medicines in the fourth quarter worth approximately $32,000. Global Retirement Partners LLC raised its stake in Revolution Medicines by 1,002.8% during the 4th quarter. Global Retirement Partners LLC now owns 397 shares of the company’s stock valued at $32,000 after buying an additional 361 shares during the last quarter. Torren Management LLC purchased a new stake in Revolution Medicines during the 4th quarter valued at $33,000. Arax Advisory Partners bought a new position in shares of Revolution Medicines during the 4th quarter valued at $38,000. Finally, Darwin Wealth Management LLC purchased a new position in shares of Revolution Medicines in the 4th quarter worth $40,000. 94.34% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. UBS Group began coverage on Revolution Medicines in a report on Friday, February 27th. They issued a “buy” rating for the company. Stifel Nicolaus reissued a “buy” rating on shares of Revolution Medicines in a report on Monday, April 20th. Guggenheim raised their target price on Revolution Medicines to $205.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Piper Sandler boosted their price target on Revolution Medicines to $172.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Finally, Evercore restated an “outperform” rating on shares of Revolution Medicines in a research note on Tuesday, April 14th. Three research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Revolution Medicines has a consensus rating of “Buy” and a consensus price target of $123.72.

Insider Buying and Selling

In other news, COO Margaret A. Horn sold 29,600 shares of the firm’s stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $160.12, for a total value of $4,739,552.00. Following the transaction, the chief operating officer owned 154,647 shares of the company’s stock, valued at $24,762,077.64. This trade represents a 16.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Jack Anders sold 2,722 shares of Revolution Medicines stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $156.12, for a total value of $424,958.64. Following the transaction, the chief financial officer directly owned 123,269 shares in the company, valued at approximately $19,244,756.28. The trade was a 2.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 226,917 shares of company stock worth $35,065,702. Company insiders own 7.60% of the company’s stock.

Revolution Medicines Trading Up 1.7%

Shares of Revolution Medicines stock opened at $165.81 on Tuesday. Revolution Medicines, Inc. has a 1-year low of $34.00 and a 1-year high of $166.84. The company’s fifty day simple moving average is $148.43 and its 200-day simple moving average is $114.24. The company has a debt-to-equity ratio of 0.19, a current ratio of 6.80 and a quick ratio of 6.80. The stock has a market capitalization of $35.25 billion, a PE ratio of -23.45 and a beta of 1.40.

Revolution Medicines (NASDAQ:RVMD) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($2.29) EPS for the quarter, missing the consensus estimate of ($1.83) by ($0.46). During the same period in the previous year, the firm posted ($1.13) earnings per share. As a group, equities analysts anticipate that Revolution Medicines, Inc. will post -7.94 earnings per share for the current year.

Revolution Medicines Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.